Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

Rhea-AI Summary

Tyra Biosciences (NASDAQ: TYRA) announced two poster presentations at the 2026 ASCO Genitourinary (GU) Cancers Symposium, held February 26-28, 2026 in San Francisco.

Posters on dabogratinib (formerly TYRA-300) include ctDNA monitoring in metastatic urothelial cancer (Abstract 809) and a SURF302 Phase 2 trial in non-muscle invasive bladder cancer (TPS886), both presented February 27, 2026 at 11:30 AM–12:45 PM PST. Posters will be posted on TYRA's investor relations website after the presentations.

Key Figures

Number of ASCO GU abstracts: 2 abstracts Cash & equivalents: $274.9M R&D expense: $25.5M +3 more

6 metrics

Number of ASCO GU abstracts 2 abstracts 2026 ASCO Genitourinary Cancers Symposium

Cash & equivalents $274.9M As of September 30, 2025 (Q3 2025 results)

R&D expense $25.5M Q3 2025 research and development spend

G&A expense $7.5M Q3 2025 general and administrative spend

Net loss $29.9M Q3 2025 net loss

Farallon ownership 5.6% 2,984,818 TYRA shares reported in Schedule 13G

Market Reality Check

Price: $31.58 Vol: Volume 657,830 is below t...

normal vol

$31.58 Last Close

Volume Volume 657,830 is below the 20-day average of 783,808 (relative volume 0.84x). normal

Technical Shares at $33.30, trading above the 200-day MA of $16.45 and within 2.03% of the 52-week high $33.99.

Peers on Argus

TYRA was up about 0.8% with mixed peer moves: BCAX up 6.08%, PVLA up 3.11%, SEPN...

1 Up

TYRA was up about 0.8% with mixed peer moves: BCAX up 6.08%, PVLA up 3.11%, SEPN up 2.56%, while RIGL was down 3.0%. Momentum scanner only flagged PVLA with a 19.55% move, suggesting TYRA’s action was stock-specific rather than a broad biotechnology move.

Common Catalyst Several biotech peers, including PVLA and BCAX, also had conference- and clinical-related headlines, consistent with a period of sector newsflow around scientific and investor events.

Historical Context

5 past events · Latest: Feb 19 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Investor conferences	Neutral	+6.6%	Announcement of multiple investor conference appearances and webcasts.
Jan 15	Earnings date notice	Neutral	-0.9%	Scheduling of another company’s earnings release and conference call.
Dec 01	Leadership appointments	Positive	-7.8%	New COO and Chief Regulatory Officer added to support dabogratinib programs.
Nov 12	Investor events	Neutral	+0.7%	Participation in Jefferies and Piper healthcare investor conferences.
Nov 05	Earnings and pipeline	Neutral	-3.6%	Q3 2025 financials and updates on dabogratinib Phase 2 studies and FDA-cleared IND.

Pattern Detected

Recent TYRA news has usually seen modest, aligned reactions, with one notable divergence on leadership appointments that was followed by a -7.76% move.

Recent Company History

Over the past six months, TYRA has highlighted investor conference participation on Nov 12, 2025 and Feb 19, 2026, a leadership strengthening announcement on Dec 1, 2025, and Q3 2025 financial and clinical updates on Nov 5, 2025. Conference-related items generated small positive or neutral moves, while the leadership update coincided with a larger -7.76% decline. Today’s ASCO GU poster news fits into a pattern of ongoing clinical and visibility milestones.

Market Pulse Summary

This announcement highlights TYRA’s advancing dabogratinib program with two posters at the 2026 ASCO...

Analysis

This announcement highlights TYRA’s advancing dabogratinib program with two posters at the 2026 ASCO GU meeting, covering ctDNA monitoring in metastatic urothelial cancer and a Phase 2 trial in non-muscle invasive bladder cancer. In recent quarters, TYRA reported Q3 cash of $274.9M and a net loss of $29.9M, while expanding clinical activity. Investors may watch forthcoming trial readouts, additional conference data, and regulatory disclosures as key milestones.

Key Terms

ctDNA, FGFR3, metastatic urothelial cancer, phase 2, +1 more

5 terms

ctDNA medical

"ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib"

Circulating tumor DNA (ctDNA) is tiny fragments of genetic material shed by cancer cells into the bloodstream, like breadcrumbs that can reveal a tumor’s presence and genetic makeup without needing a biopsy. For investors, ctDNA matters because tests and technologies that detect and analyze these fragments can speed diagnosis, track treatment response, and signal relapse, creating commercial opportunities in diagnostics, personalized therapies, and monitoring services.

FGFR3 medical

"FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300)"

FGFR3 is a gene that makes a protein sitting on the surface of cells which helps control growth and division, like a light switch that tells a cell when to grow. Changes in FGFR3 can drive certain cancers or other growth disorders, so tests and drugs that target it can be important for diagnosing disease, selecting patients for treatments, and creating new therapies — all of which affect the commercial prospects and risk profile of biotech investments.

metastatic urothelial cancer medical

"ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib"

Metastatic urothelial cancer is a late-stage cancer that began in the lining of the urinary tract (usually the bladder) and has spread to other parts of the body. For investors, it matters because the condition drives demand for advanced treatments, clinical trials, and regulatory approvals; outcomes of those trials and approvals can significantly affect the commercial prospects and valuation of companies developing therapies, much like a new product breakthrough reshapes a market.

phase 2 medical

"A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

non-muscle invasive bladder cancer medical

"FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302)"

A form of bladder cancer that is confined to the inner lining of the bladder and has not grown into the deeper muscle layer; think of it like a stain on wallpaper rather than damage to the wall’s studs. It matters to investors because it has different treatment, monitoring and recurrence patterns than deeper cancers, driving demand for repeated outpatient procedures, local therapies and diagnostic tests that affect revenue, trial design and pricing dynamics in healthcare markets.

AI-generated analysis. Not financial advice.

CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts have been accepted for presentation at the 2026 ASCO^® Genitourinary (GU) Cancers Symposium (ASCO GU). The meeting is being held February 26-28, 2026, in San Francisco, California.

Details of the poster presentations are below:

Title: "ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial"

• Abstract Number: 809
• Session: Poster Session B: Prostate Cancer and Urothelial Carcinoma
• Date and Time: February 27, 2026, 11:30 AM–12:45 PM PST
• Presenting Author: Andrew J. Murtha, BSc, University of British Columbia, Vancouver, BC, Canada

Title: "A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (formerly TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302)"

• Abstract Number: TPS886
• Session: Trials in Progress Poster Session B: Urothelial Carcinoma
• Date and Time: February 27, 2026, 11:30 AM–12:45 PM PST
• Presenting Author: Gautam Jayram, MD, Urology Associates, Nashville, TN

More information can be found at the ASCO GU website. The posters will be available on the IR page of TYRA's website following presentation at ASCO GU: https://ir.tyra.bio.

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA's lead precision medicine stemming from SNÅP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor. Oral dabogratinib's current planned clinical development includes three Phase 2 studies: SURF303 for low-grade upper tract urothelial carcinoma, SURF302 for intermediate risk non-muscle invasive bladder cancer, and BEACH301 for pediatric achondroplasia. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, CA.

For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.

Contact:
Amy Conrad
aconrad@tyra.bio

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-announces-poster-presentations-at-the-2026-asco-genitourinary-gu-cancers-symposium-302695042.html

SOURCE Tyra Biosciences

FAQ

What posters is Tyra Biosciences (TYRA) presenting at ASCO GU 2026?

Tyra is presenting two posters: ctDNA monitoring in FGFR3-altered metastatic urothelial cancer and the SURF302 Phase 2 trial in NMIBC. According to the company, Abstract 809 and TPS886 will be presented on February 27, 2026 at 11:30 AM–12:45 PM PST.

When and where will TYRA present the SURF301 ctDNA monitoring poster at ASCO GU 2026?

TYRA's SURF301 ctDNA monitoring poster (Abstract 809) is scheduled for February 27, 2026 at 11:30 AM–12:45 PM PST in Poster Session B. According to the company, the presenting author is Andrew J. Murtha, BSc.

What is the focus of the SURF302 poster for TYRA (ticker TYRA) at ASCO GU 2026?

The SURF302 poster describes a Phase 2 multicenter, open-label study of dabogratinib in FGFR3-altered low-grade, intermediate-risk NMIBC. According to the company, the abstract number is TPS886 and the presenter is Gautam Jayram, MD.

Will TYRA post the ASCO GU 2026 posters online after the presentations?

Yes, TYRA will make the posters available online after presentation. According to the company, the posters will be posted on the investor relations page of TYRA's website following the ASCO GU presentations.

Which sessions at ASCO GU 2026 include TYRA poster presentations and how are they categorized?

Both TYRA posters appear in Poster Session B: one in Prostate Cancer and Urothelial Carcinoma and one in Trials in Progress Urothelial Carcinoma. According to the company, both are scheduled February 27, 2026 at 11:30 AM–12:45 PM PST.

Who are the presenting authors for TYRA's ASCO GU 2026 posters and their affiliations?

Presenters are Andrew J. Murtha, BSc from University of British Columbia for Abstract 809, and Gautam Jayram, MD from Urology Associates, Nashville for TPS886. According to the company, both will present on February 27, 2026 at 11:30 AM–12:45 PM PST.